Insight Molecular Diagnostics (IMDX) Equity Ratio: 2020-2025
Historic Equity Ratio for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Sep 2025 value amounting to -0.21.
- Insight Molecular Diagnostics' Equity Ratio fell 251.34% to -0.21 in Q3 2025 from the same period last year, while for Sep 2025 it was -0.21, marking a year-over-year decrease of 251.34%. This contributed to the annual value of -0.35 for FY2024, which is 228.02% down from last year.
- According to the latest figures from Q3 2025, Insight Molecular Diagnostics' Equity Ratio is -0.21, which was down 1,062.95% from 0.02 recorded in Q2 2025.
- In the past 5 years, Insight Molecular Diagnostics' Equity Ratio registered a high of 0.82 during Q1 2021, and its lowest value of -0.35 during Q4 2024.
- Over the past 3 years, Insight Molecular Diagnostics' median Equity Ratio value was 0.17 (recorded in 2024), while the average stood at 0.15.
- As far as peak fluctuations go, Insight Molecular Diagnostics' Equity Ratio surged by 33.97% in 2021, and later crashed by 251.34% in 2025.
- Quarterly analysis of 5 years shows Insight Molecular Diagnostics' Equity Ratio stood at 0.41 in 2021, then declined by 16.18% to 0.34 in 2022, then decreased by 20.23% to 0.27 in 2023, then tumbled by 228.02% to -0.35 in 2024, then slumped by 251.34% to -0.21 in 2025.
- Its last three reported values are -0.21 in Q3 2025, 0.02 for Q2 2025, and 0.17 during Q1 2025.